Screener
Kyverna Therapeutics, Inc. KYTX Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $30,073 | $37,433 |
| General and administrative | 11,294 | 9,975 |
| Total operating expenses | 41,367 | 47,408 |
| Loss from operations | (41,367) | (47,408) |
| Interest income | 2,327 | 2,825 |
| Interest expense | (667) | (25) |
| Other expense, net | (21) | (27) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s total operating expenses?
- Kyverna Therapeutics, Inc. (KYTX) reported total operating expenses of $41.37M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s total operating expenses changed year-over-year?
- Kyverna Therapeutics, Inc.'s total operating expenses decreased by 12.7% year-over-year, from $47.41M to $41.37M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s total operating expenses?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s total operating expenses has grown at a 65.0% compound annual growth rate (CAGR), from $62.41M to $169.83M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Kyverna Therapeutics, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude